Learning Objectives: 

1. Describe the epidemiology and pathogenesis of Giant-Cell Arteritis

2. Discuss the role of IL-6 on CRP production 

3. Review the effects of tocilizumab on CRP

4. Discuss the GiACTA trial findings and their clinical applications

Disclosures:

Stockholder in Gilead Sciences, Inc.

Additional Instructions: 

The corresponding journal article is attached for your review. 

CME Code: GECJOM

Location: virtual (by WebEx only)
Directions: If you are having trouble accessing WebEx, please contact Isaac Smith at [email protected]. 

Streaming: Yes, via WebEx. Link:  https://dukemed.webex.com/meet/is120

Meeting Number/Access Code: 470 543 135  (you will not need this if you use link above)

Call-in number: 1-650-479-3207